AICAR

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

• Cardiovascular instability or active cardiac arrhythmia: AICAR affects cardiac adenosine metabolism and can influence heart rate and rhythm; contraindicated in subjects with unstable cardiac conditions. Limited / unverified
• Insulin therapy or sulfonylurea use without clinical supervision: AICAR's GLUT4 upregulation and glucose uptake enhancement creates additive hypoglycemia risk with insulin or insulin secretagogues. Limited / unverified
• Metformin use: both AICAR and metformin activate AMPK; overlapping activation intensifies the glucose-lowering and metabolic effects; monitor closely. Limited / unverified
• Gout or hyperuricemia: AICAR increases uric acid levels through purine catabolism pathway modulation; in subjects with gout, elevated baseline uric acid, or reduced renal uric acid clearance, AICAR may precipitate gout flares. Limited / unverified
• Renal impairment: AICAR and its metabolites are renally cleared; impaired elimination may cause accumulation and exaggerated pharmacological effects. Limited / unverified
• Active malignancy: AMPK activation has complex effects in cancer metabolism; AICAR's anti-proliferative effects have been noted in some cancer models, but its metabolic support of oxidative phosphorylation in other tumor types is not fully characterized. Limited / unverified
• Athletes competing under WADA anti-doping regulations: AICAR is explicitly listed on the WADA Prohibited List as an AMPK activator. Limited / unverified
• Known hypersensitivity to AICAR or nucleoside analog compounds. Limited / unverified
• Pregnancy: purine metabolism alteration is not established as safe in fetal development. Limited / unverified
• Breastfeeding: no safety data. Limited / unverified
• Severe hepatic impairment: AICAR metabolism and the downstream purine synthesis pathway changes may be unpredictable with impaired hepatic function. Limited / unverified

Side effects (limited evidence)

• Hypoglycemia: the most significant acute adverse effect; AICAR drives aggressive glucose uptake via GLUT4 in muscle tissue; risk is highest when dosed fasted without planned exercise; always pre-workout, always with subsequent energy expenditure. Limited / unverified
• Severe lethargy post-clearance: as AICAR washes out, the metabolic state driven by ZMP-induced AMPK activation resolves; a crash-like fatigue episode is reported by a majority of users after the dose clears, particularly with higher doses; this is a direct pharmacological consequence of the metabolic demand AICAR imposed. Limited / unverified
• Elevated uric acid (hyperuricemia): a well-characterized adverse effect from clinical cardiology data; AICAR increases purine catabolism through its adenosine mechanism, elevating urate production; particularly relevant in subjects predisposed to gout. Limited / unverified
• Headache: commonly reported; possibly related to adenosine system activity and cerebral vasodilation effects. Limited / unverified
• Nausea: reported in clinical trial data at higher doses; dose-related. Limited / unverified
• Injection site irritation: redness, swelling, pain at subcutaneous injection site; the large doses required (10-25mg) mean larger injection volumes than most peptides. Limited / unverified
• Cardiac rhythm effects: AICAR modulates cardiac adenosine signaling, which has electrophysiological implications; generally mild at research doses but warrants monitoring in subjects with pre-existing arrhythmias. Limited / unverified
• Fatigue and muscle soreness: reported during the active dosing window as the metabolic program shifts; paradoxical given the "exercise mimetic" characterization but consistent with the metabolic reorganization. Limited / unverified
• Potential AMPK overstimulation impacting muscle protein synthesis: sustained mTOR suppression from prolonged AICAR use may impair muscle hypertrophy signaling; this is the mechanistic basis for the strict 4-week maximum cycle length. Limited / unverified
• Lactic acid accumulation at high doses: theoretical; AICAR at very high doses can saturate oxidative phosphorylation pathways and shift toward glycolytic energy production with lactate production. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding